Lowering bad cholesterol really aggressively helps prevent heart attacks and strokes in people who already have heart disease, but it doesn’t actually help them live longer — which scientists call the 'cholesterol mortality paradox'.
See the scientific wording
In patients undergoing secondary cardiovascular prevention, high-intensity LDL cholesterol lowering reduces the incidence of cardiovascular events but does not reduce total mortality compared to low- or moderate-intensity therapy, a phenomenon known as the 'LDL cholesterol mortality paradox'.
Indication only — weak evidence
One low-scoring study points this way, but the evidence is still early.
What the research says
1 study reviewedSupporting (1)
Statins and the cholesterol mortality paradox
Editorial/OpinionHuman2017
The study found that stronger cholesterol-lowering treatments reduce heart problems but don’t help people live longer overall, which is exactly what the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Lowering bad cholesterol really aggressively helps prevent heart attacks and strokes in people who already have heart disease, but it doesn’t actually help them live longer — which scientists call the 'cholesterol mortality paradox'.
Evidence from Studies
Supporting (1)
Community contributions welcome
Statins and the cholesterol mortality paradox
The study found that stronger cholesterol-lowering treatments reduce heart problems but don’t help people live longer overall, which is exactly what the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of High- vs Low/Moderate-Intensity Statin Therapy on Cardiovascular Events and All-Cause Mortality in Secondary Prevention
Systematic review of randomized controlled trials comparing high-intensity vs low- or moderate-intensity LDL-lowering therapy (e.g., statins, PCSK9 inhibitors) in adults with established cardiovascular disease, reporting cardiovascular event rates and all-cause mortality over ≥1 year follow-up.
Double-Blind Randomized Trial of High-Intensity vs Moderate-Intensity Atorvastatin on Mortality and Cardiovascular Outcomes in Post-MI Patients
Large, multicenter, double-blind RCT assigning patients with prior myocardial infarction to high-intensity vs moderate-intensity statin therapy, with blinded outcome adjudication for major adverse cardiovascular events (MACE) and all-cause death over 3–5 years.
Prospective Cohort Study of LDL-Lowering Intensity and Long-Term Mortality in Patients with Prior Coronary Artery Disease
Nationwide prospective cohort of patients with prior cardiovascular events, tracking LDL-lowering therapy intensity, LDL levels achieved, incident cardiovascular events, and all-cause mortality over ≥5 years with multivariable adjustment.
Case-Control Study of High-Intensity Statin Use in Patients Who Died vs Survived After Secondary Prevention Diagnosis
Matched case-control study where cases are patients who died from any cause after secondary prevention diagnosis, controls are survivors, comparing prior use of high- vs low/moderate-intensity LDL-lowering therapy.
National Survey on LDL-Lowering Therapy Intensity and Patient-Reported Outcomes in Secondary Prevention Populations
Cross-sectional analysis of a nationally representative health survey including patients with cardiovascular disease, assessing current LDL-lowering intensity, recent cardiovascular events, and self-reported survival status.